Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin Labs, a specialty pharmaceutical company, has entered into a distribution agreement under which Mission Pharmacal Company has granted Paladin the exclusive Canadian rights to market and sell Urocit-K.
Subscribe to our email newsletter
Urocit-K 540mg strength is approved for sale in Canada and is indicated for the treatment of calcium and uric acid kidney stones. Financial terms of the deal were not disclosed. In the US, Urocit-K is available in 540mg and 1080mg strengths.
Jonathan Goodman, president and CEO of Paladin, said: “We intend to launch Urocit-K 540mg and submit the 1,080mg formulation for approval in 2009. Urocit-K complements our broad urology franchise which includes Testim for the treatment of male hypogonadism and Trelstar for the treatment of prostate cancer. We expect Urocit-K to fulfill an unmet need for kidney stone patients in Canada.”